• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bicycle Therapeutics establishes U.S. operations

Bicycle Therapeutics establishes U.S. operations

May 26, 2016
CenterWatch Staff

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as president and chief business officer. In this newly created role, Deegan will be responsible for leading Bicycle Therapeutics’ business development activities and establishing a U.S. team aligned with the Company’s focus on oncology clinical development.

“Our expansion into the U.S. in one of the world’s preeminent biotechnology hubs is an important step as we transition to a clinical-stage company with our first Bicycle Drug Conjugate program for oncology entering clinical testing next year,” said Kevin Lee, Ph.D., chief executive officer of Bicycle Therapeutics. “Ros brings proven experience in business development, finance, operations and commercial development.”

Deegan joined Bicycle Therapeutics from Trevena, where she most recently served on the senior leadership team as senior vice president, Business Development and Operations, and previously held the role of head of Finance and Operations. Prior to joining Trevena, Deegan was director of Business Development at GSK in the U.S. and, prior to that, she served as director of Operations for GSK’s Centre of Excellence for External Drug Discovery (CEED) and as Marketing Manager for GSK’s U.K. launch of Bonviva for post-menopausal osteoporosis.

“I am excited to join Bicycle, which has strong potential to create a new class of drugs with important advantages in delivering toxins to tumours, and broad applicability in a range of therapeutic areas,” said Deegan. “Bicyclic peptides hold the potential to deliver greater potency, specificity and penetration than current modalities, with more rapid clearance from the body. Our U.S. operations will play a central role for Bicycle as we advance our near-term oncology programs and enter collaborations across a range of diseases.”

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing